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Dwyer9, Timothy R. Rebbeck10, Peter A. Kanetsky10, Homer Wilcox11, Klaus Busam12, Lynn From13 and
Marianne Berwick1,14, for the GEM Study Group
Cyclin-dependent kinase inhibitor type 2A (CDKN2A) has been identified as a major melanoma susceptibility
gene based on the presence of germline mutations in high-risk melanoma families. In this study, we sought to
identify and characterize the spectrum of CDKN2A mutations affecting p16 inhibitor of cyclin-dependent kinase
type 4 (INK4a) in individuals with melanoma using a population-based study design. DNA samples from 1189
individuals with incident multiple primary melanoma (MPM) and 2424 with incident single primary melanoma
unselected for family history of melanoma were available for screening of CDKN2A (p16INK4a) mutations.
Variants were classified for functional impact based on intragenic position, existing functional data, sequence,
and structural analysis. The impact of individual mutations and functional groupings was assessed by comparing
frequencies in cases of MPM versus cases with a single first primary melanoma, and by comparing the reported
incidence rates in first-degree relatives. Our results show that mutations occur infrequently in these high-risk
groups, and that they occur mainly in exons 1a and 2. Rare coding variants with putative functional impact are
observed to increase substantially the risk of melanoma. With the exception of the variant in position 34 of
CDKN2A of known functional consequence, the remaining rare variants in the non-coding region have no
apparent impact on risk.
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INTRODUCTION
The cyclin-dependent kinase inhibitor type 2A (CDKN2A)
gene is located on human chromosome 9p21 and
encodes two protein products of great interest owing to
biological functions that suggest they are putative
tumor suppressors (Serrano et al., 1993; Kamb et al., 1994;
Nobori et al., 1994; Hara et al., 1996; Kamijo et al., 1997).
The first one, p16 inhibitor of cyclin-dependent kinase
type 4 (INK4a) (MIM 600160), is a product of the splicing
of exons 1a, 2, and 3 (Serrano et al., 1993). Splicing of
exons 1b and 2 in an alternative reading frame produces
p14ARF (Mao et al., 1995; Quelle et al., 1995; Stone et al.,
1995). During the cell cycle, p16INK4a regulates the
G1–S transition by preventing the hyper-phosphorylation of
pRB and the consequent release of transcription factors
involved in DNA synthesis (S-phase). This is accomplished
by direct binding of p16INK4a to and inhibition of the
cyclin-dependent kinases 4 and 6 (Cdk4,6) (Serrano et al.,
1993). p14ARF is capable of inducing cell cycle arrest by
inhibiting MDM2-mediated degradation of p53 (Pomerantz
et al., 1998).
CDKN2A and CDK4 have been identified as melanoma
susceptibility genes based on the discovery of germline
mutations in multiple-case families (Hussussian et al., 1994;
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Kamb et al., 1994): only six melanoma families harboring
CDK4 mutations have been identified worldwide to date
(Zuo et al., 1996; Soufir et al., 1998, Molven et al., 2005).
Thus, the major gene known to be associated with
the development of melanoma in families is CDKN2A.
The prevalence of mutations in this gene among incident
cases of melanoma has been estimated previously to be
0.2% (Aitken et al., 1999). However, this estimate was
obtained by screening six specific CDKN2A mutations in
a selected subset of melanoma cases. There are few studies
in which CDKN2A mutations have been screened throughout
the entire coding region to determine the risk associated
with the development of sporadic melanoma (MacKie et al.,
1998; Monzon et al., 1998; Burden et al., 1999; Hashemi
et al., 2000; Tsao et al., 2000; Berwick et al., 2004; Peris
et al., 2004) and the numbers of participants in these studies
were small.
Our study involved population-based ascertainment
of patients with an incident second- or higher-order
primary melanoma (denoted MPM for multiple primary
melanoma) and population-based ascertainment of incident
cases diagnosed with a single first primary melanoma
(SPM). All patients were screened for mutations affecting
p16INK4a. In previous reports from this study we have
shown that there is a strong association between melanoma
risk and p16INK4a mutations that we have classified
as ‘‘functional’’ (Berwick et al., 2006), and we have also
shown that the incidence of melanoma in first-degree
relatives is higher for MPM than SPM cases (Begg et al.,
2005). In this article, we present a detailed accoun-
ting of all of the variants identified in the study, and we
use both of these types of comparison to provide predic-
tions of which types of variants provide the strongest
association with risk of the disease, by grouping the
variants on the basis of functional characteristics and
bioinformatics tools.
RESULTS
Screening of mutations
The total number of eligible individual subjects with DNA
was 3,680. Of these, a total of 67 did not amplify CDKN2A
after multiple attempts, leaving 3,613 for analysis (2,424 SPM
and 1,189 MPM). A total of 93 of these participants are
reported in our results as both SPM and MPM in view of the
fact that both the first and the subsequent primaries occurred
during our case accession periods (see Begg et al. (2006) for
rationale) and so the final number of individuals analyzed is
3,520.
The initial screening by denaturing high-performance
liquid chromatography revealed 1,833 potentially positive
PCR fragments in 1,575 study participants. Sequencing
confirmed 44 different nucleotide changes identified in the
following regions: 50 UTR (n¼28 patients), in the coding
region (n¼ 289 patients), in intron 1 (n¼ 24 patients), and in
the 30 UTR (n¼1492 patients). Figure 1 depicts the
chromatograms and electropherograms corresponding to the
six new germline variants found. These new variants have
been submitted to dbSNP (reference numbers received
September 2005–NCBI_ss No.: 46566490, 46566491,
46566492, 46566493, 46566494, and 46566495). The
CDKN2A variants found, the prevalences of the variants
among patients with SPM and MPM, and the numbers of first-
degree affected relatives are shown in Table 1. All the
nucleotide changes found in or around exons 1a, 2, and 3 are
also shown.
The variants in Table 1 are also annotated on the basis of
available evidence that the variant affects the normal function
of p16INK4a, based on in vitro assays that measure binding of
p16INK4a to CDK4 and CDK6, inhibition of CycD-CDK in
transfected insect cells, protein–protein interactions in yeast,
and cell cycle arrest in mammalian cells as previously
reported by others (Koh et al., 1995; Ranade et al., 1995;
Reymond and Brent, 1995; Parry and Peters, 1996; Harland
a
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Figure 1. Detection of CDKN2A variants by denaturing high-performance liquid chromatography and direct sequencing. (a) Top row, depicts the
chromatographic heteroduplex profiles obtained in six samples bearing novel variants. The windows highlight the homoduplex or normal profile obtained from
wild-type internal controls run at the same gradient and temperature conditions (see Materials and Methods). (b) Bottom row, corresponds to the
electropherograms obtained in the same samples, confirming the presence of nucleotide changes (arrows). Note that for the variant Arg124Cys, reverse
sequencing is shown and corresponds to the forward C-T change in c.370.
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Table 1. Position, functional characteristics, and prevalence of the variants identified in GEM
CDKN2A
nucleotide changes1
Effect on
p16INK4A
Effect on
p14ARF2
In vitro and
other supporting
evidence3
Frequency in
SPM, N (%)
Frequency in
MPM, N (%)
Number of first-
degree relatives
with melanoma
Variant found in
familial
melanoma4
50UTR
() 70 G/A No change N/A 0 1 (0.08) 0/5
() 34 G4T Novel AUG (35) N/A Yes5 2 (0.08) 6 (0.50) 7/52 1 family
() 34 G4T+c.442
G4A
Novel AUG
(35)+Ala148Thr
N/A Yes5 0 1 (0.08) 1/6 1 family (34
G4T)
() 33 G4C No change N/A No change6 8 (0.33) 6 (0.52) 0/118
() 33 G4C and
c.50+37 G4C
No change N/A 1 (0.04) 0 0/8
() 25 C4T No change N/A 2 (0.08) 0 0/13
() 14 C4T No change N/A No change6 2 (0.08) 1 (0.09) 0/10
Exon 1a
c.8_9insGG
CGGCGG
GGAGCAG
CATGG
AGCC
In-frame insertion 8
aa duplication7
N/A Yes8 6 (0.25) 0 2/40
c.8_33del In-frame deletion 8
aa
N/A 0 2 (0.17) 1/21
c.47 T4G Leu16Arg N/A 0 2 (0.17) 2/23 1 family
c.67 G4A Gly23Ser N/A 0 1 (0.08) 1/5
c.67 G4C+c.442
G4A
Gly23Arg+
Ala148Thr
N/A 1 (0.04) 0 1/10
c.71 G4C Arg24Pro N/A Yes8,9,10 2 (0.08) 0 2/13 4 families
c.87_89delG Ala30fs, stop 52 N/A Yes, derived11 1 (0.04) 0 0/5
c.87_89delG+
c.442 G4A
Ala30fs, stop
52+Ala148Thr
N/A Yes, derived11 1 (0.04) 0 0/8
c.95 T4C Leu32Pro N/A 0 2 (0.17) 0/12 2 families
c.123 G4A Pro41Pro N/A 4 (0.16) 0 1/31
c.123 G4A+c.146
T4C
Pro41Pro+Ile49Thr N/A Yes9,10,11 0 1 (0.08) 0/6
c.131_132insA Tyr44stop N/A Yes, derived10 0 1 (0.08) 0/5
c.132 C4A Tyr44stop N/A Yes, derived10 0 1 (0.08) 1/6
c.136 C4A Arg46Arg N/A 1 (0.04) 0 0/5
c.146 T4C Ile49Thr N/A Yes8,9,10,12 1 (0.04) 0 0/9
c.146 T4G Ile49Ser N/A 0 1 (0.08) 2/7 1 family
c.149 A4C Gln50Pro N/A Yes9,13 1 (0.04) 1 (0.08) 2/7
Intron 1
c.50+21 G/A No change N/A 1 (0.04) 0 0/6
c.50+37 G/C No change N/A 14 (0.58) 6 (0.52) 2/113
c.50+54 G/A No change N/A 2 (0.08) 0 0/13
c.51–5 G4A No change N/A 1 (0.04) 0 0/5
Exon 2
c.159 G4A Met53Ile Asp109Asn Yes8,9,10 1 (0.04) 2 (0.17) 0/9
c.159 G4C Met53Ile Asp109His Yes8,9,10 1 (0.04) 1 (0.08) 0/15 8 families
c.170 C4T Ala57Val Arg112Arg 0 2 (0.17) 0/11
c.173 G4A Arg58Gln Pro113Pro 1 (0.04) 0 1/5
c.174 A4C Arg58Arg Ser114Arg 1 (0.04) 0 0/5
c.179 C4T Ala60Val Gly115Gly 1 (0.04) 0 0/6
c.247 C4T His83Tyr Ala138Val Yes9,10,12,13 0 1 (0.08) 0/5
c.249 C4A His83Gln Arg139Arg 1 (0.04) 0 0/6
Table 1 continued on the following page
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et al., 1997; Monzon et al., 1998; Liu et al., 1999; Ruas et al.,
1999; Walker et al., 1999; Yarbrough et al., 1999; Becker
et al., 2001; Loo et al., 2003; Ghiorzo et al., 2004).
Classification of GEM variants
Consistent with our earlier reports examining relative risk and
penetrance (Begg et al., 2005; Berwick et al., 2006) we use
the term ‘‘functional’’ to define rare mutations in the coding
region that change the amino acid for either p16INK4a or
p14ARF, regardless of whether in vitro evidence of function-
ality is available. We analyze separately the single common
non-synonymous variant, the previously well-documented
Ala148Thr polymorphism, and the common changes in
positions 29 and 69 after the stop codon, also referred to as
‘‘nt 500’’ and ‘‘nt 540’’. We included in the ‘‘functional’’
category the G4T alteration at position 34 in the 50UTR
which is known to decrease translation of the wild-type p16
on the basis of in vitro studies (Liu et al., 1999). These
mutations are highlighted in bold type in Table 2. Variants
with low frequency presumed to be ‘‘non-functional’’
comprise silent mutations and those changes found in intron
1 and in the 50UTR that do not alter or are not known to alter
p16INK4a based on the literature. We also elected to classify
the Ala143Thr variant as ‘‘non-functional’’ as this variant lies
outside the ankyrin repeat motifs within a region that is not
required for the protein to bind and inhibit CDK4. As this
variant was observed in only a single patient, its exclusion
from the ‘‘functional’’ category has no appreciable effect on
Table 1. continued
CDKN2A
nucleotide changes1
Effect on
p16INK4A
Effect on
p14ARF2
In vitro and
other supporting
evidence3
Frequency in
SPM, N (%)
Frequency in
MPM, N (%)
Number of first-
degree relatives
with melanoma
Variant found in
familial
melanoma4
c.295 C4T Arg99Trp Pro154Leu 0 1 (0.08) 0/6
c.301 G4T Gly101Trp Arg156Leu Yes8,9,10,12,13 1 (0.04) 5 (0.42) 7/47 16 families
c.304 G4A Ala102Thr Gly157Asp 0 1 (0.08) 0/4
c.306 G4A+c.322
G4A
Ala102Ala+
Asp108Asn
Ala158Thr+
Arg163Gln
No change6 1 (0.04) 0 0/5 1 family (Asp108Asn)
c.318 G4A+c.442
G4A
Val106Val+
Ala148Thr
Ala162Thr 2 (0.08) 1 (0.08) 1/22
c.322 G4A Asp108Asn Arg163Gln No change6 1 (0.04) 0 1/2 1 family
c.334 C4G Arg112Gly Pro167Arg 0 2 (0.17) 1/13 1 family
c.370 C4T Arg124Cys N/A 1 (0.04) 0 0/3
c.373 G4C Asp125His N/A 3 (0.12) 0 0/18 1 family
c.384 G4A Arg128Arg N/A 1 (0.04) 0 0/9
c.427 G4A+c.442
G4A
Ala143Thr+
Ala148Thr
N/A 1 (0.04) 0 0/5
c.442 G4A Ala148Thr N/A No change6
predominantly
nuclear staining14
159 (6.6) 70 (6.1) 45/1445
30 UTR
*29 CC N/A N/A 1769 (73%) 876 (74%) 490/17084
*29 CG N/A N/A 628 (26%) 294 (25%) 164/5844
*29 GG N/A N/A 26 (1.07%) 20 (1.68%) 10/310
*69 CC N/A N/A 1957 (81%) 950 (80%) 515/18740
*69 CT N/A N/A 425 (18%) 212 (18%) 132/4033
*69 TT N/A N/A 29 (1.20%) 22 (1.86%) 13/353
GEM, Genes Environment and Melanoma Study; fs, frameshift; N/A, not applicable.
Note that mutations defined as ‘‘functional’’ (see text) are highlighted in bold type.
1Nucleotide 1 is the A of the ATG-translation initiation codon of p16INK4A.
2Changes occurring outside the p14ARF coding region (human p14ARF numbering) or downstream of stop codon.
3Includes any known report of in vitro assays performed.
4Comparison made with results obtained with the largest study conducted in melanoma families to date (Bishop et al., 2002).
5Decreases transcription of wild-type p16 (Liu et al., 1999).
6Existing in vitro data shows no change from wild type (Koh et al., 1995; Ranade et al., 1995; Reymond and Brent, 1995).
7Amino acids inserted: AAGSSMEP.
8Nuclear mislocalization and/or abnormal staining pattern, functional impairment (Walker et al., 1999; Ghiorzo et al., 2004; Becker et al., 2005).
9Decreased or null-binding affinity to CDK4/6 (Ranade et al., 1995; Reymond and Brent, 1995; Harland et al., 1997; Monzon et al., 1998; Loo et al., 2003).
10Partial or total lack of growth arrest/inhibition (Koh et al., 1995; Parry and Peters, 1996; Walker et al., 1999; Yarbrough et al., 1999; Becker et al., 2001).
11p16 proteins with equal or less than 120 residues lack CDK-binding capacity (Parry and Peters, 1996).
12Inhibition of Rb phosphorylation (Ranade et al., 1995; Parry and Peters, 1996).
13Protein instability and/or temperature sensitive (Parry and Peters, 1996; Ruas et al., 1999; Loo et al., 2003).
14Pattern of staining in p16 variant-transfected cells (Walker et al., 1999).
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the results of our statistical analyses. This variant was
previously identified as a germline variant in an indolent
case of chronic lymphocytic leukemia (Pinyol et al., 2000).
We recognize that our classification of rare variants as
‘‘functional’’ or ‘‘non-functional’’ is a combination of
definitive categorization (in terms of changes in amino acid
and the restriction to rare variants) and availability of
extraneous evidence from in vitro studies, but we believe
that this represents the most appropriate categorization to
highlight the magnitude of CDKN2A on disease risk based on
current knowledge.
Rare variants
We found 33 functional mutations in 65 patients (Table 1). A
number of silent mutations were identified. Eleven of the
variants observed had been previously identified in melano-
ma-prone families (Bishop et al., 2002; Table 1, column 8). In
some instances we identified different changes from those
reported in melanoma-prone families affecting the same
residue such as the Gly23Ser and Gly23Arg (Table 1) versus
the Gly23Asp (Bishop et al., 2002). The variants appear to be
randomly distributed throughout exons 1a and 2, but none
were identified in exon 3.
Frequently occurring variants
Most variants are rare, appearing in just one or a few study
participants. The exceptions are the common Ala148Thr
polymorphism present in 234 (6.9%) individuals, and the C-
G and C-T variants found in the 30 UTR (positions 29 and 69
after the stop codon, or nt 500 and 540), which were
Table 2. Correlation of biological subgroups of variants with risk
SPM MPM Melanoma in relatives Odds ratio MPM versus SPM1 Rate ratio in relatives2
Functional mutations3 30 35 33/417 (7.9%) 3.9 (2.3–6.7) 3.0 (1.8–5.0)
Previously identified in melanoma-prone families4 11 20 23/213 (10.8%)
Not previously identified in melanoma-prone families 19 15 10/204 (4.9%)
In vitro evidence of functionality 17 20 22/233 (9.4%)
No in vitro evidence of functionality 13 15 11/184 (6.0%)
Non-functional mutations 37 15 3/336 (0.9%) 0.8 (0.4–1.6) 0.4 (0.1–1.2)
50 UTR region (excluding SNP in 34) 13 8 0/154 (0.0%)
Intron 1 18 6 2/137 (1.5%)
Silent 6 0 1/45 (2.0%)
Non-functional frequent polymorphisms 1028 522 301/9874 (3.1%)
Ala148Ala wild type 2234 1084 589/21373 (2.8%)
Ala148Thr heterozygote5 160 70 45/1450 (3.1%) 1.0 (0.8–1.1) 1.2 (0.8–1.7)
*29 (nt 500) CC reference 1769 876 490/17049 (2.9%)
*29 (nt 500) CG 628 294 164/5840 (2.8%) 1.0 (0.9–1.1) 1.0 (0.8–1.3)
*29 (nt 500) GG 26 20 10/310 (3.2%) 2.0 (1.1–3.9) 0.9 (0.4–2.4)
*69 (nt 540) CC reference 1957 950 515/18700 (2.8%)
*69 (nt 540) CT 425 212 132/4034 (3.3%) 1.0 (0.8–1.2) 1.2 (0.9–1.5)
*69 (nt 540) TT 29 22 13/353 (3.7%) 1.5 (0.8–2.7) 1.6 (0.8–3.2)
All GEM Study participants with successful sequencing 2424 1189 667/23241 (2.9%)
All GEM Study participants 2470 1210 680/23905 (2.9%)
MPM, multiple primary melanoma; SPM, single primary melanoma.
1Odds ratio from a logistic regression model comparing the MPM versus SPM frequencies in the given category, using all other patients as the referent
category, adjusted for patient age at diagnosis of the index melanoma and center.
2Rate ratio from a Poisson regression analysis in which the first-degree relatives are the units of analysis, and age at diagnosis is the outcome, adjusted for
patient age, sex, and center.
3Mutations present in the coding region or known to change the transcription.
4Bishop et al., 2002.
5There is one patient that had Ala143Thr+Ala148Thr with a single primary tumor and no family history of melanoma.
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identified in 945 (27%) and 671 (19%) of study participants,
respectively.
Mutations affecting p14ARF
Table 1 shows the p14ARF amino-acid changes using the
numbering for the human protein as annotated in GenBank
(NP478102.1) and referred to by some investigators (Laud
et al., 2005; Zhang et al., 2005), although mutants have been
frequently reported using the murine numbering (Weber
et al., 2000; Bishop et al., 2002). Most of the Genes
Environment and Melanoma Study (GEM) CDKN2A exon 2
nucleotide changes translated into missense mutations in
p14ARF (Table 1), and one of our mutants (Ala138Val)
resides in the nucleolar localization site. Our study did not
include genotyping of exon 1b, and so we do not have a full
census of p14ARF variants.
Variants and risk for melanoma
As originally reported in Berwick et al. (2006), the risk of
melanoma was greatly increased in individuals with a
functional mutation (Table 2). MPM was more frequent in
patients with variants previously identified in melanoma-
prone families, and the frequency of occurrence of melano-
ma in relatives of these probands was more than twice as
great, though neither of these differences reaches statistical
significance. However, there was essentially no difference for
either of these measures when mutations with prior in vitro
evidence of functionality were compared with those with no
such evidence. The frequency of occurrence of non-
functional mutations was similar in MPM and SPM cases,
1.2 versus 1.5%, respectively, and no increase in melanoma
risk among relatives was observed (relative risk¼ 0.4, 95%
confidence interval: 0.1–1.2). For the three polymorphisms,
heterozygous variants have essentially identical risk to the
wild type. There is suggestive but inconclusive evidence that
homozygous variants may exhibit modestly increased risk (for
both polymorphisms in the 30 UTR region). Comparisons of
the functional variants on the basis of bioinformatic
predictors were hindered by the fact that bioinformatic
scores are available only for mutations occurring at residues
that have homology with other protein families, and so these
analyses are hindered by small sample sizes and relatively
low statistical power. However, there is suggestive evidence
that Polymorphism Phenotyping (Polyphen) and the Position
Specific Scoring Matrix difference may have value in
predicting which variants confer the greatest risk. Details
are available in Table S2 and S3.
DISCUSSION
Cancer genes are initially identified from studies of families
that exhibit multiple cases of the disease. However, to obtain
a comprehensive, representative view of the impact of such
genes on risk, population-based studies are necessary. In this
study, we examined rare variants in the tumor suppressor
gene CDKN2A by identifying a large population-based
sample of incident cases of melanoma (SPM), and a large
population-based sample of patients experiencing a subse-
quent primary melanoma (MPM). The results show that
mutations occur infrequently even in these high-risk groups,
and that mutations affecting p16INK4a occur mainly in exons
1a and 2.
In addition to providing a comprehensive catalogue of the
variants observed in the study (Table 1), we sought to
examine the evidence regarding the degree to which
melanoma risk may vary on the basis of the nature of the
mutation. The results support the following conclusions. Rare
p16INK4a variants that change the amino-acid residue or for
which there exists in vitro evidence of a functional effect (for
variants outside the coding regions) demonstrate a substantial
increase in risk of melanoma, whereas non-functional rare
variants demonstrate no evidence for an increase in risk.
Results from comparisons of MPM versus SPM cases and from
the analyses of familial aggregation were consistent with
these conclusions. Common polymorphisms demonstrate no
impact on the risk of melanoma, with the proviso that there is
a suggestion of a modest increase in risk for individuals with
homozygous variants. Comparisons on the basis of subgroup-
ings of the rare ‘‘functional’’ variants were generally either
not statistically significant or inconsistent, although we
caution that our data are too sparse to address the issue of
risk variation among these functional variants reliably.
Several groups have addressed the functional properties of
p16INK4a-mutated alleles using various in vitro assays that in
general measure binding of p16INK4a to CDK4 and CDK6,
inhibition of p16 by CycD-CDK in transfected insect cells,
protein–protein interactions in yeast, and cell cycle arrest in
mammalian cells. Most reports concluded that the majority of
the missense mutations cause loss of function, and the loss of
function in some cases has a range of effects (Parry and
Peters, 1996). Among the other mutants identified in our
study, the c.87_89delG produces a frameshift in codon 30
that leads to a stop codon in codon 52. This mutant has not
been directly tested in laboratory assays but its functional
relevance is inferred based on the knowledge that p16INK4a
proteins with less than 120 residues lack the capacity to bind
to and inhibit CDK (Parry and Peters, 1996). Similarly, the C
to A transversion on the third position in codon 44 and the
c.131_132insA gives rise to a stop codon (Tyr44stop). As
indicated above, this truncated p16INK4a mutant is not
capable of inhibiting CDK4.
We identified several new point mutations: Arg58Gln,
Ala60Val, His83Gln, Arg99Trp, Ala102Thr, and Arg124Cys
(Figure 1). Of these, the Arg58Gln, Ala60Val, and Arg124Cys
variants do not alter p14ARF and no additional information
from in vitro studies is currently available to assess the impact
of these changes on p16. His83 interacts with the Arg31 in
the CDK6 molecule and other previously reported changes in
this position (His to Tyr) showed a defective binding of p16 to
Cdk6 and failure to induce cell cycle arrest (Yarbrough et al.,
1999). The substitution in position 99 consists of a charge
change (positive to neutral), whereas Ala102Thr may disrupt
the intra ankyrin III interaction. Additionally, the transitions
c.295 C-T and c.304 G-A identified in GEM cases
produce changes in p14ARF.
The prevalence of the previously well-documented
Ala148Thr polymorphism is similar to previous reports in
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melanoma cases, and based on in vitro experiments it is
functionally indistinguishable from the wild-type p16INK4a
(Koh et al., 1995; Ranade et al., 1995; Reymond and Brent,
1995). Although this variant has been recently associated
with increased risk of breast cancer (Debniak et al., 2005a), it
does not seem to segregate with melanoma (Hussussian et al.,
1994; Walker et al., 1995; Harland et al., 1997; Debniak
et al., 2005b) and this is confirmed in our study. Interestingly,
when melanoma cells were transfected with this variant, cells
showed a predominantly nuclear staining by immunohisto-
chemistry compared to an even nuclear/cytoplasmic staining
observed in wild-type p16INK4a-transfected cells (Walker
et al., 1999). The other common polymorphisms present at nt
500 and at nt 540 (*29 and *69) were found among GEM
participants with higher frequencies than the 12–15%
reported by others ((Ruas and Peters, 1998); National Institute
of Environmental Health Sciences NIEHS http://egp.gs.wa-
shington.edu – accessed June 2005). Although neither of
these variants causes a change in the amino-acid sequence of
p16INK4a and the functional importance is unknown, our
interest in targeting this region was motivated by the fact that
30 UTR regions may be involved in the regulation of gene
expression by controlling nuclear export, polyadenylation,
translation rates, and messenger RNA degradation. These
variants do not segregate with melanoma in melanoma prone
families according to some reports (Harland et al., 1997).
Others have found that the G variant in position 500 (*29)
appeared associated with familial risk to melanoma, although
the degree of ethnic contribution remains to be established
(Aitken et al., 1999). Interestingly, in a small study, Straume
et al. (2002) found that presence of the C-T (*69) transition
might be associated with low-grade vertical growth phase
melanomas and might improve survival in melanoma
carriers. Our results appear to suggest modest elevation of
risk in carriers of the homozygous variants. This increase in
risk is statistically significant only for the nt500 variant, but
there is no confirmatory evidence of elevation of risk among
relatives.
In summary, we identified 44 different variants in
CDKN2A(p16INK4a) in a population-based study. Of these,
33 were functionally relevant and were identified in 35 cases
of MPM and 30 cases of SPM. To the best of our knowledge,
six have not been previously reported: Arg58Gln, Ala60Val,
His83Gln, Arg99Trp, Ala102Thr, and Arg124Cys. Rare
functional variants increased the risk of melanoma signifi-
cantly. Further subclassification of these variants failed to
identify strong evidence of differences in melanoma risk
between the variants.
MATERIALS AND METHODS
Study participants
Subjects were recruited through an international multi-center
population-based case–control study of melanoma, the GEM. The
GEM population consists of incident cases of melanoma identified in
eight population-based registries and one hospital center (that sees
about 50 percent of the melanoma diagnosed in the state of
Michigan) in nine geographic regions of the world: New South
Wales (Australia); Tasmania (Australia); British Columbia (Canada);
Ontario (Canada); Turin (Piemonte, Italy); California (Orange County
and San Diego/Imperial Organization for Cancer Control, USA);
MIUSA; NJUSA; and NC. The study was approved by the
Institutional Review Board at Memorial Sloan-Kettering Cancer
Center (MSKCC) and at each participating institution. The study was
conducted according to the Declaration of Helsinki Principles. All
participating subjects signed informed consent.
Participants were individuals diagnosed with either a single first
invasive primary melanoma (SPM) or with a second- or higher-order
invasive or in situ melanoma (MPM). All subjects completed a
telephone interview in English (or in Italian in Turin). The study was
approved by the institutional review board in all centers. All study
participants signed informed consent, provided a sample of buccal
cells or blood for DNA extraction, and completed an interview,
which included the collection of detailed information on the
occurrence of melanoma in the participant’s first-degree relatives.
Further details of the study design and its rationale can be found in
Begg et al. (2006).
Laboratory methods
DNA was collected from subjects by means of buccal swabs
(88.5%), which were mailed to the participants, or from blood
samples (in 11.5% of the participants). Our methods for identifying
sequence variation have been described in detail in a previous
article (Begg et al., 2005). Briefly, PCR products spanning exons 1a,
2, and 3 plus the adjacent intronic regions of all samples were
initially screened by denaturing high-performance liquid chromato-
graphy analysis (Orlow et al., 2001). Samples were amplified using
primers described previously (Hussussian et al., 1994; Kamb et al.,
1994) with few modifications. For interested readers, these are
defined in Table S1. All samples showing an altered denaturing high-
performance liquid chromatography chromatographic profile were
re-amplified from genomic DNA in an independent PCR reaction for
DNA sequencing. Sequencing was accomplished for exons 1a, 2,
and 3 of the CDKN2A gene, the exons that code for the p16INK4a
protein. We did not sequence exon 1b, which, together with exons 2
and 3, codes for the p14ARF protein. Mutations were considered
‘‘functional’’ if they were in the coding region and if the
replacement, deletion, or insertion of one or more nucleotides
changed the amino-acid sequence for p16INK4a or p14ARF or both,
or if they were in a non-coding region and were known to inhibit
transcription of wild-type p16INK4a based on previous in vitro
studies (e.g., Liu et al., 1999). The primers extended beyond either
end of the coding regions. However, the primers did not extend to
the deep intronic mutation IVS2-105, which has recently been
associated with melanoma in some melanoma-prone families
(Harland et al., 2005).
An additional exon 3 fragment was tested by pyrosequencing to
determine presence of variants in position 540 (Ronaghi, 2003).
Fragments were amplified in a reaction containing 0.2 mM each of the
following primers: forward 50-NCCCGATTGAAAGAACCAGAGA-30
and reverse 50-biotin-AAAGCGGGGTGGGTTGTG-30, 1.5 mM
MgCl2, 200mM dNTP and 0.05 U/ml Taq Polymerase, and PCR
buffer. The cycling consisted of a denaturation at 951C for 5 minutes
followed by 45 cycles of 951C for 15 seconds, 601C for 30 seconds,
721C for 15 seconds, with a final extension at 721C for 7 minutes.
Products were immobilized and denatured at 801C for 2 minutes.
The sequencing primer (50-AGTCACCGAAGGTCC-30) was added to
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the single-stranded DNA and nucleotides dispensed automatically
by a Pyrosequencing AB PSQ96MA instrument and software
(Uppsala, Sweden). All reactions contained known controls and
pyrograms were read twice.
Statistical analysis
Empirical evidence of the likely functional relevance of individual
mutations and relevant groupings of similar types of mutations was
obtained through two separate analyses. The first analysis compared
the relative frequencies of the mutation(s) among cases of MPM
versus cases of SPM, on the premise that mutations that increase the
risk of melanoma will occur with a greater relative frequency among
MPMs (Begg and Berwick, 1997; Monzon et al., 1998; Bernstein
et al., 2004). These analyses involved the use of logistic regression,
adjusted for age at diagnosis of the index lesion, and study center.
Relevant groupings of mutations with different characteristics were
compared using Fisher’s exact test or with the Cochran–Armitage test
in the case of ordered categories, as implemented in StatXact&
software. The second analysis involved comparison of the reported
frequencies of melanoma in first-degree relatives of probands.
Probands with a mutation that increases the risk of melanoma are
more likely to report a history of melanoma in their first-degree
relatives (Begg et al., 2005). For these comparisons Poisson
regression was used to estimate rate ratios and 95% confidence
intervals, with adjustment for age and center.
Bioinformatics tools
Various sequence-based software applications were used to predict
the probability that observed variants could have a functional impact
on the protein. The first one, Sort Intolerant from Tolerant, is based
on the premise that changes in conserved amino acids within a
family of proteins or across species are more likely to have an
important impact on function (Ng and Henikoff, 2001, 2002). The
Sort Intolerant from Tolerant scores range from 0 to 1 and low scores
(o0.05) represent high probabilities that the amino acid change at a
given position affects protein function. The Position Specific Scoring
Matrix score is expressed in terms of the observed frequency of an
amino acid at each position within a block of proteins, using
homology models by aligning the change to a block. Large changes
from the alignment, or larger positive Position Specific Scoring
Matrix differences indicate that the variant is likely to have
a deleterious effect. For our prediction of these scores using
PARSESNP (Taylor and Greene, 2003, http://www.proweb.
org/parsesnp), the first three best blocks family hits were chosen
and included: IPB002110 (Ankyrin repeat signature), IPB010660
(NOD), and IPB000906 (ZU5 domain) with E-values equal or
smaller than 9 109. The third prediction tool, PolyPhen,
uses protein structure, sequence and phylogenetic information to
predict the impact on the 3D-structure and the consequences
of amino-acid changes on protein function (Sunyaev et al., 2000,
2001; Ramensky et al., 2002). PolyPhen returns a prediction of
probably damaging, possibly damaging, benign, or unknown,
derived from a numeric (PSIC) score. For the prediction of our
GEM CDKN2A mutants on the structure and/or function of
p16INK4a by PolyPhen we used web-based tools (http://www.bor-
k.embl-heidelberg.de/PolyPhen/), chose the Protein Data Bank as
structural database, and selected the following options: map to
mismatch (no), and calculate contacts (for all hits). Default options
and values were used for the sorting of hits, calculation of structural
parameters, minimal identity and maximal gap in alignment, and
threshold for contacts. We were unable to obtain Sort Intolerant from
Tolerant, Position Specific Scoring Matrix, and PolyPhen scores for
variants affecting p14ARF because of lack of family blocks with high
homology to this protein. Similarly, scores were unavailable for p16
variants located in positions with no homology with the family
blocks (see Table S3).
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